Based on the selected cut-off points of every biomarker examined in this study (Figure 4 and Figure S3), including plasma/exosomal miR-21, EpCTCs/CTM and pre-operative serum CEA/CA19-9, the Kaplan–Meier survival analyses on DFS of these biomarkers individually and combined (Figure 5 and Figure S4) to predict recurrence in patients with stage I to III CRC were investigated. This evidence concerns the gene CEACAM5 and colorectal carcinoma.